$2.06
-0.02 (-0.96%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALXO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +1 more) · FINRA short interest 13.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559Overall Response Rate (ORR) using RECIST v1.1 based on BICR assessmentOpen-label · Treatment | Phase 2 | Recruiting | Drug: Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine | Breast Cancer, Metastatic | 120 | Dec 2027 | ≤ 498 d | 2026-08-14 |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsNCT07085091Phase 1a: Incidence of dose limiting toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ALX2004, ALX2004, ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC) | 170 | Jun 2027 | ≤ 314 d | 2026-05-12 |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)NCT04675294Objective response rate per RECIST 1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: evorpacept, pembrolizumab | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 189 | 2025-03-03actual | — | 2025-08-01 |
| Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)NCT04675333Objective response rate per RECIST 1.1Randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 172 | 2025-03-03actual | — | 2025-08-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127Phase 2Randomized · Quadruple-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | 127 | 2024-05-24actual | — | 2025-08-07 |
| A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)NCT05524545First Cycle Dose limiting toxicities (DLTs)Open-label · Treatment | Phase 1 | Completed | Drug: Evorpacept, Enfortumab Vedotin | Bladder Cancer, Urothelial Carcinoma | 36 | 2025-06-27actual | — | 2025-07-25 |
| A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)NCT04417517Phase 1: Dose Limiting Toxicities (DLT)Randomized · Single-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: While intended to be a Phase 1/2 clinical study, the study did not proceed to Phase 2. | Drug: evorpacept, azacitidine | Higher Risk Myelodysplastic Syndromes | 65 | 2025-01-17actual | — | 2025-07-20 |
| A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)NCT04755244Phase 1: Dose Limiting Toxicities (DLT)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Drug: evorpacept, venetoclax, azacitidine | Acute Myeloid Leukemia, AML, Adult | 14 | 2023-05-05actual | — | 2024-11-27 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)NCT03013218Dose-limiting toxicities (Number of participants with a DLT)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: Evorpacept (ALX148), Pembrolizumab, Trastuzumab, Rituximab, Ramucirumab + Paclitaxel, 5-FU + Cisplatin | Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma | 174 | 2022-02-01actual | — | 2025-08-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19